{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-180750","form_type":"8-K","ticker":"PHAT","cik":"0001783183","company_name":"Phathom Pharmaceuticals, Inc.","filed_at":"2024-07-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.508176+00:00","generated_at":"2026-05-31T19:46:23.403849+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Phathom gets FDA approval for VOQUEZNA to treat heartburn in Non-Erosive GERD","bullets":["FDA approved VOQUEZNA (vonoprazan) 10 mg tablets for relief of heartburn associated with Non-Erosive GERD in adults.","This is the third FDA approval for VOQUEZNA; also approved for Erosive GERD and H. pylori eradication.","Approximately 45 million US adults have Non-Erosive GERD; about 15 million treated with prescription medicine annually.","Non-Erosive GERD is the largest GERD category, characterized by reflux symptoms without esophageal erosions."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-180750","json":"https://secwatch.observer/filing/0001193125-24-180750.json","markdown":"https://secwatch.observer/filing/0001193125-24-180750.md","text":"https://secwatch.observer/filing/0001193125-24-180750.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1783183/000119312524180750/0001193125-24-180750-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1783183/000119312524180750/d812423d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T19:46:23.403849+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}